Gilead Sciences, Inc. GILD NASDAQ

Gilead Sciences, Inc. (GILD) generated $10.02B in operating cash flow for fiscal year 2025. After capital expenditures of $563M, free cash flow was $9.46B.

Free cash flow margin was 32.1% of revenue. Cash conversion ratio was 1.18x, indicating earnings are backed by cash.

The company returned $4B in dividends and $1.92B in share buybacks to shareholders during the period.

Criteria supported by this page:

• HEALTH (83/100, Pass) — demonstrate the company can comfortably service its debt
• MOAT (90/100, Pass) — $9.46B (32.1% FCF margin) supports a durable competitive advantage
• INCOME (85/100) — Cash conversion ratio was 1.18x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 78/100 with 6/7 criteria passed.